Edwards Lifesciences Q3 FY2026 Earnings Call Summary

EW NYSE Healthcare 📅 2026-11-04 ⏱ ~60 sec read 🟢 Bullish

⏱️ 60-Second Brief Edwards Lifesciences · Q3 FY2026

Stock Next Day

▲ 1.46%

$99.37 → $100.82

Revenue

$1.72B

EPS

AI Sentiment

🟢 Bullish

The company delivered strong financial results, significantl…

📌 Bottom Line: Edwards Lifesciences reported robust third-quarter results, exceeding expectations with strong revenue growth and increased full-year guidance across key product categories. The company's innovative structural heart ther…

🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy. · ⚠️ Not financial advice. For informational purposes only. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-11-07 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

Edwards Lifesciences reported robust third-quarter results, exceeding expectations with strong revenue growth and increased full-year guidance across key product categories. The company's innovative structural heart therapies, particularly in TAVR and TMTT, continue to drive significant procedural growth and market adoption, reinforcing its long-term strategic position.

📊 Key Financial Metrics

Revenue $1.72B

EPS (Diluted) $3

YoY Revenue Growth 10.5%

Gross Margin 78.5%

Net Income $307.5M

AI Sentiment 🟢 Bullish The company delivered strong financial results, significantly raised its full-year guidance, and achieved multiple key clinical and regulatory milestones, indicating robust operational execution and a positive outlook for future growth.

✅ What Went Well

✅ **Strong Top-Line Growth and Raised Guidance:** Edwards Lifesciences reported Q3 sales of $1.72 billion, a 10.5% increase year-over-year, and subsequently raised its full-year 2026 sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97-$3.05, signaling robust performance and management confidence.

✅ **Exceptional TMTT Segment Performance:** The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment delivered outstanding growth, with sales increasing 44.0% to $207 million, driven by strong adoption of its diverse portfolio and new product approvals like PASCAL Precision and PASCAL Ace with Capture Clarity.

✅ **Key Clinical and Regulatory Achievements:** The company secured several significant approvals and presented practice-changing clinical data, including the PROGRESS trial for moderate AS, the final TAVR National Coverage Determination (NCD) expanding patient access, and U.S. approval of AUTUS for pediatric congenital heart disease, reinforcing its innovation leadership.

⚠️ Concerns & Risks

⚠️ A significant non-GAAP charge of $220.2 million was recorded for the impairment of an in-process research and development asset and fixed assets from an acquisition, which impacted GAAP operating income.

⚠️ The company's effective tax rate for the full year is expected to be at the high end of its 16-19% range, partly due to changes in California law restricting R&D credit usage and the uncertainty around Pillar Two taxation legislation.

⚠️ While TAVR sales grew 8.0%, the company assumes future growth will be mainly driven by continued increases in procedure volumes rather than significant share gains, suggesting a more mature market where competitive positioning is stable rather than rapidly expanding.

🔮 CEO / Management Guidance

Management expressed strong confidence in the company's trajectory, raising full-year 2026 sales growth guidance to approximately 11.5% and adjusted EPS guidance to a range of $2.97 to $3.05. They anticipate continued increases in procedure volumes, particularly in TAVR and TMTT, and project fourth-quarter sales between $1.67 billion and $1.75 billion with adjusted EPS of $0.61 to $0.69.

💬 Key Quote

We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook. — Bernard Zovighian, CEO

📅 Quarter-over-Quarter Comparison

Comparing Q3 FY2026 vs Q2 FY2026 All quarters →

Revenue $1.74B → $1.72B

EPS $691.2 → $3

Gross Margin 77.6% → 78.5%

Net Income $241.9M → $307.5M

YoY Growth 13.6% → 10.5%

Sentiment 🟢 Bullish → 🟢 Bullish

Stock Reaction -0.77% → +1.46%

🏢 About Edwards Lifesciences

Edwards Lifesciences (EW) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

EW NYSE Healthcare All Edwards Lifesciences Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

Topics: Medical Devices Cardiovascular Health Earnings Report Innovation

📁 More from Edwards Lifesciences

View all earnings summaries for Edwards Lifesciences →